Vimarsana
Biggest News Aggregation in the World

Page 4 - Alxo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alxo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alxo Today - Breaking & Trending Today

ALX Oncology (NASDAQ:ALXO) PT Raised to $17.50 at HC Wainwright - Vimarsana News

ALX Oncology (NASDAQ:ALXO) PT Raised to $17.50 at HC Wainwright

ALX Oncology (NASDAQ:ALXO – Get Free Report) had its target price upped by investment analysts at HC Wainwright from $16.00 to $17.50 in a report released on Tuesday, MarketBeat reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 174.29% from the stock’s current […]

ALX Oncology (NASDAQ:ALXO) Price Target Raised to $23.00 - Vimarsana News

ALX Oncology (NASDAQ:ALXO) Price Target Raised to $23.00

ALX Oncology (NASDAQ:ALXO – Get Free Report) had its price objective lifted by Cantor Fitzgerald from $18.00 to $23.00 in a research note issued on Wednesday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald’s price objective indicates a potential upside of 267.41% from the company’s current price. Other equities […]

Source: wkrb13.com
Stocks to Watch: Delta Apparel, Oddity Tech, ALX Oncology - Vimarsana News

Stocks to Watch: Delta Apparel, Oddity Tech, ALX Oncology

By Ben Glickman Delta Apparel said it had received an unsolicited offer to acquire its Salt Life unit. The apparel company did not say the terms of the...

ALX Oncology Reports Positive Interim Phase 2 Data From ASPEN-06 Trial Of Evorpacept For Cancer - Vimarsana News

ALX Oncology Reports Positive Interim Phase 2 Data From ASPEN-06 Trial Of Evorpacept For Cancer

Immuno-oncology company ALX Oncology Holdings Inc. (ALXO) announced Tuesday positive prespecified interim Phase 2 data from its ASPEN-06 clinical trial, a randomized multi-center international study evaluating evorpacept, the Company's CD47 blocking therapeutic, in combination with trastuzumab, CYRAMZA (ramucirumab) and paclitaxel for the treatment of patients with HER2-positive gastric/gastroesophageal junction (GEJ) cancer.

ALX Oncology Shares Surge 83% on Early Data From Clinical Trial - Vimarsana News

ALX Oncology Shares Surge 83% on Early Data From Clinical Trial

By Will Feuer Shares of ALX Oncology jumped after the developer of potential cancer treatments reported an interim analysis of early data from its Phase 2...